ArticleMalaria journal2026
Genetic diversity of the Plasmodium falciparum Pfs230 gene in four East African countries supports its potential as a malaria transmission‑blocking vaccine candidate.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundThe current wide-spread drug and insecticide resistance in malaria parasites and mosquito vectors reinforces the urgent need of innovative interventions such as stage-specific vaccines. Transmission-blocking vaccine (TBV) candidates, including Plasmodium falciparum Pfs48/45 and Pfs230 play an essential role in enabling parasite fertilization within mosquitoes. This study evaluated the genetic diversity and evolutionary dynamics of the Pfs230 gene to provide critical information on its potential as a suitable TBV candidate.
methodsThe study utilized genomic data from the MalariaGEN Pf7 database, which included samples collected from four East African countries: Ethiopia, Kenya, Tanzania, and Uganda. Genetic metrics including nucleotide diversity, haplotype diversity (Hd), Tajima's D, and Wright's fixation index (F
resultsOf the 1471 sequences retrieved, 1312 passed quality filtering and were retained for downstream analysis. Overall, nucleotide diversity of the Pfs230 gene was low across the four countries (π = 5.9 × 10
conclusionLow levels of genetic diversity and differentiation in the parasite populations was observed across the four countries suggesting that the Pfs230 gene is highly conserved, supporting its potential as a promising TBV candidate. Future studies focusing on Pfs230, alongside other key TBV targets will be essential for strengthening evidence-based needs to prioritize and incorporate this gene in the search for malaria vaccines with a broader protection against different parasite stages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.